Brief: Ono Enters Into A Drug Discovery Collaboration & Option Agreement With Shattuck Labs To Generate Bifunctional Fusion Proteins
Feb 13 (Reuters) - Ono Pharmaceutical Co Ltd 4528.T :
* ONO ENTERS INTO A DRUG DISCOVERY COLLABORATION AND OPTION
AGREEMENT WITH SHATTUCK LABS TO GENERATE BIFUNCTIONAL FUSION
PROTEINS
* ONO PHARMACEUTICAL - ONO WILL PAY TO SHATTUCK RESEARCH
FUNDING,
UP-FRONT PAYMENT, MILESTONES ON PROGRESS OF RESEARCH AND
DEVELOPMENT, COMMERCIALIZATION, UP TO $227 MILLION
Source text for Eikon: ID:
Further company coverage: 4528.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours